Kura Oncology is a clinical-stage biopharmaceutical company engaged in developing medicines for the treatment of cancer. Co.'s primary product candidate, ziftomenib, is a selective, reversible and oral small molecule inhibitor which blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene. Co.'s second product candidate, tipifarnib, is a selective and orally bioavailable inhibitor of farnesyl transferase. Co. is evaluating tipifarnib in multiple solid tumor and hematologic indications. The KURA average annual return since 2015 is shown above.
The Average Annual Return on the KURA average annual return since 2015 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether KURA average annual return since 2015 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the KURA average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|